Cannabis equities are having a moment few in the sector predicted even a year ago. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed to its highest levels of 2026, driven by a wave of institutional and retail buying ahead of a DEA administrative hearing set for June 29. That hearing, which will examine whether cannabis products broadly should move to Schedule III, has become the single biggest catalyst the sector has seen since state-legal markets began scaling nationally.
The numbers tell a striking story. MSOS posted a 103.7% one-year net asset value return as of May 31, dwarfing the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8% return over the same stretch. Three-month performance is even more telling: the ETF is up 28% while the broader marijuana benchmark actually slipped about 1%. For operators watching capital markets from the retail floor - where budroom inventory, POS terminals, and compliance logs still define daily operations more than stock tickers do - this divergence matters because it signals where investor confidence is concentrating, and it's not evenly spread across the industry. Retailers managing multi-state footprints increasingly rely on integrated systems, including pos cannabis washington deployments, to keep sales data, tax reporting, and seed-to-sale tracking aligned as scrutiny intensifies alongside investor interest. pos cannabis washington
Trulieve's NYSE Listing Reshapes the Uplisting Conversation
Trulieve Cannabis, MSOS' largest holding at roughly 30% of assets, began trading on the NYSE under the ticker TRLV this week. CEO Kim Rivers called it a "historic milestone," and she's not wrong to frame it that way - a senior U.S. exchange listing has been the industry's white whale for years, blocked largely by federal prohibition and the compliance risk that comes with it. Trulieve got there by separating its medical cannabis operations from its adult-use business, a structural move that let it satisfy exchange requirements without waiting on full federal reform. Alliance Global maintains a "Buy" rating with a C$27 price target, pointing to Trulieve's concentration in medical-only states and its exposure to expanding medical markets like Texas and Georgia as differentiators.
Why Schedule III Changes the Math for Operators
Here's the mechanism driving all this enthusiasm: Acting Attorney General Todd Blanche moved state-licensed medical marijuana products into Schedule III in April, eliminating the tax penalties tied to Section 280E for licensed medical operators. That's not a small thing. Under 280E, cannabis companies have long been barred from deducting ordinary business expenses - payroll, rent, interest - because the products remained federally illegal under Schedule I. Removing that constraint for medical operators improves earnings, frees up cash flow, and strengthens balance sheets almost overnight, without a single new customer walking through the door. Roth Capital called the broader rescheduling order "extremely favorable," citing gains in taxation treatment, capital access, and future uplisting potential.
Trump's formal nomination of Blanche to serve as permanent attorney general only reinforced the bullish read. Cresco Labs moved quickly, securing a $50 million revolving credit facility from Needham Bank that CEO Charlie Bachtell described as a "non-dilutive tool" for acquisitions and a step toward a future senior exchange listing. Tilray Brands, though not part of MSOS, has signaled it may use proceeds from its at-the-market program to pursue its own expansion.
Where the Upside - and the Risk - Actually Sits
Trulieve gets the headlines, but it's not the holding with the steepest upside on paper. Verano carries the highest projected upside among MSOS components at 195%, followed by Jushi Holdings at 183% and Cresco Labs near 99%. Green Thumb Industries, a U.S.-based retail operator, shows 70% upside - notably higher than both Trulieve and Curaleaf, the world's largest cannabis company by revenue. What's striking here is how retail sentiment has caught up to the institutional trade: Stocktwits data shows "extremely bullish" positioning on MSOS, TCNNF, and GTBIF alongside heavy message volume, with Tilray showing similar enthusiasm.
None of this changes the operational reality on the ground. Dispensary owners and multi-state operators still answer to state regulators, still file compliant packaging and lab-testing documentation, and still manage wholesale pricing pressure regardless of what happens on an exchange floor. A rescheduling decision would ease the tax burden and open banking access, but it wouldn't touch state-level license caps, social equity requirements, or the day-to-day discipline of inventory shrinkage control. Investors betting on the sector's "next big winner" should keep that distinction in mind - capital markets optimism and retail-level compliance execution are two different disciplines, and only one of them keeps a dispensary's doors open.
